Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Rotrosen

Showing results (121-130 of 157) with videos related to

Pageof 16
Sort By:
Journal of Addiction Medicine|August 14, 2023
Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOTMarissa Justen, Jennifer Scodes, Martina Pavlicova, et al.
Contemporary Clinical Trials|October 17, 2016
Corrigendum to "Extended-release naltrexone opioid treatment at jail reentry (XOR)" [Contemp. Clin. Trials 49 (2016) 57-64]Ryan D McDonald, Babak Tofighi, Eugene Laska, et al.
Contemporary Clinical Trials|April 16, 2019
Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON)Mia Malone, Ryan McDonald, Alex Vittitow, et al.
Addiction (Abingdon, England)|May 5, 2021
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysisSean M Murphy, Philip J Jeng, Kathryn E McCollister, et al.
Contemporary Clinical Trials|May 15, 2016
Extended-release naltrexone opioid treatment at jail reentry (XOR)Ryan D McDonald, Babak Tofighi, Eugene Laska, et al.
Substance Use & Misuse|August 17, 2022
Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable NaltrexoneMiranda G Greiner, Matisyahu Shulman, Jennifer Scodes, et al.
Drug and Alcohol Dependence|August 11, 2020
Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trialAli Jalali, Danielle A Ryan, Philip J Jeng, et al.
Journal of Neuroscience Methods|January 15, 2008
Network homogeneity reveals decreased integrity of default-mode network in ADHDLucina Q Uddin, A M Clare Kelly, Bharat B Biswal, et al.
Addiction (Abingdon, England)|March 23, 2024
Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorderPaul J Christine, Sara Lodi, Heather E Hsu, et al.
Contemporary Clinical Trials|April 24, 2024
Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trialMatisyahu Shulman, Scott Provost, Kaitlyn Ohrtman, et al.
Pageof 16

Showing results (121-130 of 157) with videos related to

Sort By:
Pageof 16
Journal of Addiction Medicine|August 14, 2023
Homelessness and Treatment Outcomes Among Black Adults With Opioid Use Disorder: A Secondary Analysis of X:BOTMarissa Justen, Jennifer Scodes, Martina Pavlicova, et al.
Contemporary Clinical Trials|October 17, 2016
Corrigendum to "Extended-release naltrexone opioid treatment at jail reentry (XOR)" [Contemp. Clin. Trials 49 (2016) 57-64]Ryan D McDonald, Babak Tofighi, Eugene Laska, et al.
Contemporary Clinical Trials|April 16, 2019
Extended-release vs. oral naltrexone for alcohol dependence treatment in primary care (XON)Mia Malone, Ryan McDonald, Alex Vittitow, et al.
Addiction (Abingdon, England)|May 5, 2021
Cost-effectiveness implications of increasing the efficiency of the extended-release naltrexone induction process for the treatment of opioid use disorder: a secondary analysisSean M Murphy, Philip J Jeng, Kathryn E McCollister, et al.
Contemporary Clinical Trials|May 15, 2016
Extended-release naltrexone opioid treatment at jail reentry (XOR)Ryan D McDonald, Babak Tofighi, Eugene Laska, et al.
Substance Use & Misuse|August 17, 2022
Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable NaltrexoneMiranda G Greiner, Matisyahu Shulman, Jennifer Scodes, et al.
Drug and Alcohol Dependence|August 11, 2020
Health-related quality of life and opioid use disorder pharmacotherapy: A secondary analysis of a clinical trialAli Jalali, Danielle A Ryan, Philip J Jeng, et al.
Journal of Neuroscience Methods|January 15, 2008
Network homogeneity reveals decreased integrity of default-mode network in ADHDLucina Q Uddin, A M Clare Kelly, Bharat B Biswal, et al.
Addiction (Abingdon, England)|March 23, 2024
Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorderPaul J Christine, Sara Lodi, Heather E Hsu, et al.
Contemporary Clinical Trials|April 24, 2024
Discontinuation of medication treatment for opioid use disorder after a successful course: The discontinuation phase of the CTN-0100 (RDD) trialMatisyahu Shulman, Scott Provost, Kaitlyn Ohrtman, et al.
Pageof 16